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Abstract
 
We show that a combination of the immunosuppressive drugs, vitamin D3 and Dexametha-
sone, induced human and mouse naive CD4
 
 
 
 T cells to differentiate in vitro into regulatory T
cells. In contrast to the previously described in vitro derived CD4
 
  
 
T cells, these cells produced
only interleukin (IL)-10, but no IL-5 and interferon (IFN)-
 
 
 
, and furthermore retained strong
proliferative capacity. The development of these IL-10–producing cells was enhanced by neu-
tralization of the T helper type 1 (Th1)- and Th2–inducing cytokines IL-4, IL-12, and IFN-
 
 
 
.
These immunosuppressive drugs also induced the development of IL-10–producing T cells in
the absence of antigen-presenting cells, with IL-10 acting as a positive autocrine factor for these
T cells. Furthermore, nuclear factor (NF)-
 
 
 
B and activator protein (AP)-1 activities were in-
hibited in the IL-10–producing cells described here as well as key transcription factors in-
volved in Th1 and Th2 subset differentiation. The regulatory function of these in vitro gener-
ated IL-10–producing T cells was demonstrated by their ability to prevent central nervous
system inflammation, when targeted to the site of inflammation, and this function was shown
to be IL-10 dependent. Generating homogeneous populations of IL-10–producing T cells in
vitro will thus facilitate the use of regulatory T cells in immunotherapy.
Key words: experimental autoimmune encephalomyelitis • vitamin D3 • Dexamethasone • 
T regulatory lymphocyte • autoimmunity
 
Introduction
 
CD4
 
 
 
 T cell subsets include Th1 cells producing IFN-
 
 
 
which are important for the clearance of intracellular
pathogens but also mediate autoimmune pathologies (1, 2),
and Th2 cells producing IL-4, IL-5, and IL-13 which play a
role in the clearance of extracellular pathogens but are also
implicated in allergic manifestations (1–3). IL-10 was origi-
nally isolated from Th2 cells (4) and it has been suggested
that a Th1 to Th2 switch may result in the amelioration of
organ-specific Th1-mediated autoimmune diseases (1, 5).
However, observations showing that Th2 cells may also
give rise to immunopathology (6) supported the theory for
the existence of other regulatory T cell subsets (7–11). Fur-
thermore, IL-10 can be produced by a number of different
cells including Th1 cells and by affecting APC function and
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Abbreviations used in this paper:
 
 AP, activator protein; CNS, central ner-
vous system; DC, dendritic cell; Dex, Dexamethasone; EAE, experimen-
tal autoimmune encephalomyelitis; MSCH, mouse spinal cord homoge-
nate; NF, nuclear factor; NFAT, nuclear factor of activated T cells; RAG,
recombination activating gene; VitD3, 1,25(OH)
 
2
 
-vitamin D3. 
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dendritic cell (DC)
 
*
 
 maturation (12–14) can inhibit both
Th1 and Th2 type responses, suggesting an important neg-
ative feedback role for this cytokine (15, 16). In addition, a
number of studies suggest that IL-10–producing T cells
may be induced in the absence of Th1 and Th2 responses
and are involved in establishing non responsiveness (15,
17–19). These regulatory T cells could thus be of potential
use in therapeutic intervention during inflammatory pa-
thology. For example, Bacchetta et al. in 1994 isolated
CD4
 
 
 
 T cell clones producing IL-10, IL-5, and little to no
IL-2, from SCID patients in an HLA-mismatched situation
after successful bone marrow transplantation, and these cells
were implicated for the lack of GVHD (17). Also, repeti-
tive stimulation of T cells using immature DCs as APCs
resulted in T cells producing IL-10 but no other inflam-
matory cytokines (18). However, the low proliferative
capacity of these populations of IL-10–producing regula-
tory cells provides a limitation for their use in clinical ther-
apy. Various studies have suggested that the timing and
possibly the localization of IL-10 production may critically
affect its immunoregulatory function (20). Thus, an effi-
cient strategy to avoid such complications would be the ad-
ministration of antigen-specific T cells that produce IL-10
only upon stimulation through the TCR. However, such
an alternate strategy has been hindered so far by the diffi-
culty to reproducibly obtain a homogeneous population of
IL-10–producing T cells in large numbers.
The generation in vitro of a regulatory T cell subset
(named Tr1) by stimulating naive CD4
 
 
 
 T cells in the
presence of IL-10, or a combination of IL-4 and IL-10, has
previously been reported (21). However, Tr1 cells not only
produce IL-10 but in addition inflammatory cytokines such
as IFN-
 
 
 
 and IL-5 which can mediate inflammatory pa-
thologies (100% of the IL-10–producing cells also make IL-5
[21]). Moreover, generating these cells using this protocol
has proved difficult, as these culture conditions also invari-
ably induce significant numbers of Th1 and Th2 cells (our
results and reference 22) which suggest that IL-10 is probably
not sufficient by itself to induce a homogeneous population
of Tr1 cells. Indeed Levings et al. have recently attempted
to obtain more homogeneous populations of IL-10–pro-
ducing T cells by use of IFN-
 
 
 
 as a possible cofactor. This
led to a population of T cells producing high levels of IL-
10 but in addition IFN-
 
 
 
 (23). Taken together, these find-
ings question the use of these regulatory cells in adoptive
immunotherapy, as they may simultaneously exacerbate al-
ternate inflammatory pathologies.
We postulated that a combination of immunosuppressive
drugs, 1,25(OH)
 
2
 
-vitamin D3 (VitD3) and Dexamethasone
(Dex), known to inhibit key transcription factors involved
in the regulation of a number of inflammatory cytokines
genes, would allow the development of a homogeneous
population of IL-10–producing cells. VitD3 inhibits Th1-
mediated autoimmune diseases including experimental au-
toimmune encephalomyelitis (EAE), a model for multiple
sclerosis (24, 25), and is currently used topically to treat
psoriasis in humans (26). VitD3 affects APCs as well as
lymphocytes and inhibits the production of a wide variety
of pro-inflammatory and subsequent Th1 responses (26–
28). Glucocorticoids (GCs), including Dex, are among the
most potent immunosuppressive and antiinflammatory
drugs currently available and are efficacious in the treat-
ment of both Th1- and Th2-associated inflammatory dis-
eases including rheumatoid arthritis and asthma (29, 30).
GCs inhibit both T cells and APCs at the level of prolifera-
tion and cytokine production (31–33). Recently, it has
been shown that Dex enhanced IL-10 and reduced IL-4,
IL-5, and IL-13 production in human CD4
 
 
 
 and CD8
 
 
 
 T
cells (34). In addition, myelin basic protein (MBP)-specific
Th2 cell lines generated in vitro in the presence of Dex plus
IL-4 were shown to protect rats from EAE, although these
cells lines would have undoubtedly contained Th2 cells (35).
Most importantly, VitD3 and Dex are known to inhibit
the activation and action of important transcription factors
involved in cytokine gene regulation, such as nuclear fac-
tor of activated T cells (NFAT), activator protein (AP)-1,
and nuclear factor (NF)-
 
 
 
B (30, 36–38). The repression of
IL-2 gene transcription by VitD3 occurs via the vitamin D
receptor (VDR)-dependent inhibition of NFAT and AP-1
complex formation (39). It has also been described that
VitD3 mediates downregulation of NF-
 
 
 
B p50 and c-Rel
protein expression in T cells (38). Glucocorticoids have
been shown to interfere with the function of transcription
factors such as AP-1 and NF-
 
 
 
B via protein–protein inter-
actions (30, 36), and in addition to inhibit IL-4 and possi-
bly IL-2 gene expression by interfering with NFAT-
dependent transactivation (37).
Here, we describe a novel strategy to induce the develop-
ment of IL-10–producing regulatory T cells, using a combi-
nation of the immunosuppressive drugs VitD3 and Dex,
which are known to impair cytokine gene regulation. In ad-
dition, we define factors that positively and negatively regu-
late their development, and provide novel findings regard-
ing the possible molecular mechanisms for the physiological
development of these IL-10–producing regulatory T cells.
 
Materials and Methods
 
Mice and Reagents.
 
DO11.10 mice transgenic for an oval-
bumin
 
323–339
 
 specific TCR
 
   
 
(40) and DO11.10 mice crossed
with recombination activating gene (RAG)
 
 
 
/
 
 
 
 mice were used as
a source of antigen specific T cells. CSJLF1/J mice were obtained
from The Jackson Laboratory. BALB/cAnN were obtained from
Taconic Farms. All mice were housed under specific pathogen-
free conditions and were used between 6–12 wk of age. Mono-
clonal anti-cytokine antibodies used in culture were anti–IL-4
(clone 11B11), anti–IL-12 (clone C17.8.20, a gift of G. Trinch-
ieri, The Wistar Institute, Philadelphia, PA) and anti–IFN-
 
 
 
(XMG 1.1; DNAX; as referenced in reference 41). Anti–mouse
CD3 and CD28 mAbs used for T cell stimulation were purchased
from BD PharMingen. mAbs used for T cell preparation were
anti-B220, anti-CD8
 
 
 
, anti–Mac-1, anti-CD4-FITC, and anti-
L-selectin-PE (all mouse specific; BD PharMingen). Anti–IL-
10R mAb (1B1.3) was as described (42) and contained undetect-
able levels of endotoxin.
 
Culture Conditions with Mouse T Cells.
 
Naive CD4
 
  
 
L-select-
in
 
high
 
 T cells were prepared as described previously (41). Cultures 
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were set up with 2.5 
 
 
 
 10
 
5
 
 sorted naive T cells, 5 
 
 
 
 10
 
6
 
 splenic
APCs (
 
 
 
-irradiated, 3,000 rads), and 0.6 
 
 
 
M OVA
 
323–339
 
 peptide.
Naive T cells were also stimulated using coated anti-CD3 (10
 
 
 
g/ml) and anti-CD28 (1 
 
 
 
g/ml) and restimulated as described
(43). When added, VitD3 at 4 
 
 
 
 10
 
 
 
8
 
 M (BIOMOL Research
Labs) and Dex at 10
 
 
 
8
 
 M (Sigma-Aldrich) were present during
the entire stimulation period. After each round of stimulation,
cells were stimulated with PMA (50 ng/ml) and ionomycin (500
ng/ml), and after 2 h Brefeldin A (10 
 
 
 
g/ml) was added and 2 h
later the cells were harvested and fixed with 2% paraformalde-
hyde (Sigma-Aldrich). Cells were then permeabilized with 0.5%
saponin and stained with the cytokine antibodies as described
(41). T cells were also restimulated using PMA/ionomycin at 5 
 
 
 
10
 
5
 
 per ml and supernatants were harvested at 48 h for assessment
of cytokine production by ELISA.
 
Culture Conditions with Human T Cells.
 
Human peripheral blood–
derived CD4
 
 
 
 T lymphocytes from healthy donors were posi-
tively selected using antibody-conjugated Dynabeads and then
negatively depleted of CD45RO
 
 
 
 cells to give a 
 
 
 
98%
CD4
 
 
 
CD45RA
 
 
 
 population. The cells were cultured with plate-
bound anti-CD3, 2 
 
 
 
g/ml soluble anti-CD28 and 50 U/ml IL-2.
Some groups also received 50 U/ml IL-4 (NBS), 5 
 
 
 
 10
 
 
 
8
 
 M
Dex (Sigma-Aldrich), 10
 
 
 
7
 
 M VitD3, and 5 
 
 
 
g/ml each of anti–
IL-4 and anti–IFN-
 
 
 
 and anti–IL-12. The cultures underwent
four rounds of stimulation and were then restimulated with anti-
CD3, anti-CD28, and IL-2 alone for 18 h for intracellular cyto-
kine staining, with addition of 2 
 
 
 
M monensin 2 h after the initi-
ation of the culture. Alternatively culture supernatants were
harvested at 48 h and IL-4, IL-5, IL-10, and IFN-
 
 
 
 content ana-
lyzed by ELISA.
 
Real-time Quantitative PCR (TaqMan) Analysis.
 
RNA from
the different T cell subsets was extracted using RNeasy Kit
(QIAGEN) according to the manufacturer’s protocol and reverse
transcribed with oligo dT14–18 (Life Technologies) and random
hexamer primers (Promega) using standard protocols. cDNA was
analyzed for the expression of IL-10, T-bet, erm, GATA-3, c-maf,
and ubiquitin by PCR assay using a PerkinElmer ABI Prism 5700
Sequence Detection System (PerkinElmer). Quantification of tar-
get gene expression was calculated by correcting the values rela-
tive to the expression of ubiquitin.
 
Preparation of Nuclear Extracts and EMSA for AP-1 and NF-
 
 
 
B.
 
Prior to the preparation of nuclear extracts, 1–2 
 
 
 
 10
 
7
 
 T cells
were incubated in cRPMI with 2% FCS for 5 h and then acti-
vated with cross-linked anti-CD3 for 2 h. Nuclear extracts were
prepared as described (44). In brief, cells were pelleted and cell
membranes then disrupted by brief (1 min) incubation in PSB
buffer (50 mM HEPES, 100 mM NaF, 10 mM NaPPi, 2 mM
NaVO4, and 4 mM EDTA) with 0.2% Nonidet P-40 (NP-40)
(Boehringer) and 10 mM MgCl
 
2
 
. Cells were then washed in
0.05% NP-40 with sucrose and 10 mM MgCl
 
2
 
 and nuclei lysed
in 0.1% NP-40 in PSB. Protease inhibitors (leupeptin and aproti-
nin; Sigma-Aldrich), and Pefabloc (Boehringer) were added to all
solutions used. EMSA were performed for AP-1 (c-fos) and NF-
 
 
 
B (p65) according to the manufacturer’s protocol (Geneka Bio-
technology).
 
EAE Protocol.
 
Mouse spinal cord homogenate (MSCH) was
prepared from 8–12-wk-old BALB/cAnN mice as described
previously (45). For active induction of EAE, mice were immu-
nized intradermally over three right flank sites with a total of 150
 
 
 
l of a PBS-oil emulsion containing 4 mg of MSCH and 75 
 
 
 
g
of heat killed 
 
Mycobacterium tuberculosis 
 
(strain H37RA; Difco).
Immunized mice were challenged over three left flank sites with
the same MSCH preparation at day 7. Pertussis toxin (100 ng;
List Bio Lab) was intravenously injected at day 1 and 8. OVA (10
 
 
 
g) was precipitated using alum and injected intracranially 4 d
before immunization and 1–3 
 
 
 
 10
 
6
 
 cells were intravenously in-
jected 3 d before immunization with MSCH. As controls, some
mice were injected with alum alone to assess the influence of the
intracranial injection by itself on the outcome of the response.
Alternatively, mice were injected intraperitoneally with OVA
(10 
 
 
 
g or 1 mg) precipitated using alum, or not injected with
OVA (controls). Anti–IL-10R mAb or isotype control mAbs (1
mg per mouse) were administered, 1 h before injection of the
cells as well as once a week during the EAE experiment. In
BALB/c mice the incidence of disease is 30–70% while in
CSJLF1/J mice, it is 90–100% with a greater than 50% mortality
rate within 1 wk after the onset of the disease (45). Clinical signs
of EAE were scored as described previously (45). For histopa-
thology, mice were killed by CO
 
2
 
 asphyxiation and spinal cords
removed, fixed in 10% formalin and embedded in paraffin
blocks. Sections were stained with hematoxylin and eosin for
light microscopy as described.
 
Results
 
Vit/Dex Enhances the Development of IL-10–producing T
Cells.
 
Naive CD4
 
 
 
 T cells were stimulated using APC
and OVA in the presence of VitD3 and Dex in order to as-
sess their role on T cell differentiation. VitD3 promoted
the differentiation of naive OVA-specific TCR-transgenic
CD4
 
 
 
 T cells, stimulated with antigen and APCs, into Th2
cells, enhancing IL-5 and IL-10 and reducing IFN-
 
 
 
 pro-
duction relative to populations cultured with no additions
(neutral condition; Fig. 1 A). Dex, in contrast, inhibited
both IL-5 and IFN-
 
 
 
 production and slightly enhanced the
production of IL-10 (Fig. 1 A). Neither of the drugs had a
significant effect on IL-4 production. Using the two drugs
in combination (Vit/Dex) led to the development of an in-
creased number of IL-10–producing T cells and decreased
numbers of IFN-
 
 
 
, IL-4, and IL-5–producing cells (Fig. 1
B, and data not shown). This correlated with protein levels
in the culture supernatants (Fig. 1 A). As already suggested
in previous studies (22), addition of exogenous IL-10 (as
originally described to generate Tr1 cells [21]) gave rise to
heterogeneous populations of T cells containing IL-10–
producing T cells as well as Th2 cells producing IL-10 and
IL-4 (Fig. 1, A and B).
 
Inhibition of Th1 and Th2 Type Cytokines Enhances the De-
velopment of Vit/Dex-induced IL-10–producing T Cells.
 
To
determine whether Vit/Dex-derived T cells can develop
independently of both Th1 and Th2 polarizing cytokines,
we performed similar stimulations in the presence of neu-
tralizing mAbs to IL-12, IFN-
 
 
 
, and IL-4. Under these
conditions, VitD3 and Dex synergized to give rise to a
population of T cells producing IL-10 but no IL-4, IL-5,
or IFN-
 
 
 
, and low amounts of IL-2 (Fig. 2 A, and data not
shown). The inhibition of both Th1 and Th2 polarizing
cytokines was essential for this effect (data not shown). Ab-
solute percentages of IL-10-producing cells as well as abso-
lute amounts of IL-10 protein were decreased compared
with those obtained in the absence of neutralizing mAbs
(Fig. 1) which can be explained by the removal of IL-4– 
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dependent IL-10–producing cells (including Th2 cells).
Identical results were obtained when T cells were isolated
from DO11.10 RAG
 
 
 
/
 
 
 
, which do not contain any
CD4
 
 
 
CD25
 
 
 
 T cells. These results using the combination
Vit/Dex plus neutralizing mAbs were unique and in con-
trast to cells cultured similarly but with VitD3 or Dex
alone, where only very low numbers of cells produced IL-
10. Strikingly, cells cultured with IL-10 as described previ-
ously (21), but here in the absence of IL-4, IL-12, and
IFN-
 
 
 
, lost their capacity to make IL-10 and resembled
undifferentiated cells in that they mainly produced IL-2
(Fig. 2 A). Remarkably, inhibition of Th1- and Th2-polar-
izing cytokines enhanced the growth of IL-10–producing
T cells generated with Vit/Dex. The expansion of the cells
increased from 2–4-fold (Vit/Dex alone) to 15–25-fold
(Vit/Dex plus anti–IL-12, IFN-
 
 
 
, and IL-4 mAbs) after
three rounds of stimulation. This suggests that IL-10–pro-
ducing T cells can be controlled by Th1 and Th2 cells, and
has enormous implications for the physiological interplay
between these cells during an immune response.
 
Vit/Dex Can Mediate Its Effect on T Cells in the Absence of
APCs.
 
VitD3 and Dex have been reported to have a
strong inhibitory effect on APCs (26–28, 30). Both drugs
can indeed affect the maturation of DCs (28, 46), which
might be decisive for the development of IL-10–producing
T cells (18, 19). However, we show that Vit/Dex also in-
duced the development of IL-10–producing T cells when
naive CD4
 
 
 
 T cells were stimulated with anti-CD3 and
anti-CD28 only (Fig. 2 B), in contrast to cells activated in
the presence of Vit or Dex alone (data not shown). In fact,
culture of T cells in the complete absence of APCs allowed
the development of much higher numbers of IL-10–pro-
ducing cells in response to Vit/Dex (increased from 33%
with APCs, to 70% without APCs), and very low numbers
of IL-4–producing cells (Fig. 2 B) or IFN-
 
 
 
–producing
cells (data not shown). This was a reproducible increase as
compared with cultures containing APCs and was seen in
all of four experiments. Again, identical results were ob-
tained using either DO11.10 RAG
 
 
 
/
 
 
 
, DO11.10, or
BALB/c mice
 
Vit/Dex Enhances the Development of Human IL-10–pro-
ducing T Cells.
 
In view of the potential implications of
our results regarding immunotherapy, conditions for gen-
erating IL-10–producing T cells in the mouse, using Vit/
Dex and anti-CD3 and anti-CD28 stimulation in the com-
plete absence of IL-4 and IFN-
 
 
 
, were reproduced with
human T cells. Naive human CD4
 
 CD45RA  T cells cul-
tured under these conditions resulted in T cells producing
high levels of IL-10 and no IL-4, IL-5, or IFN-  (Fig. 3
A). This was also achieved in the presence of APC (data
not shown). Similarly to our results using mouse T cells
(Fig. 2 B), the combination of Vit/Dex led to an enhanced
percentage of human IL-10–producing T cells, compared
with the effects of Vit and Dex alone (Fig. 3 B). These cells
did not produce any IL-4 or IFN- . The ability to generate
human T cells producing IL-10 in the absence of Th1 or
Th2-type cytokines, is a significant step toward their po-
tential application in adoptive immunotherapy.
IL-10–producing T Cells Induced by Vit/Dex Can Prevent
EAE. CD4  T cells producing primarily IL-10 would be
predictably potent inhibitors of inflammatory responses.
However, before they could be considered regulatory T
cells, it was necessary to prove this directly in vivo. To
demonstrate the regulatory capacity of the Vit/Dex in-
duced IL-10–producing T cells to inhibit inflammatory
pathologies, OVA-specific DO11.10 T cells were trans-
ferred into mice 3 d before the induction of EAE with
MSCH. These cells included Th1 and Th2 cells as well as
cells derived under neutral conditions, in the presence of
VitD3 alone, or Dex alone as controls, or T cells derived
Figure 1. VitD3/Dex enhances the development of IL-10–producing cells. Purified OVA-specific naive CD4  T cells were activated using OVA323–339
peptide and APCs in the presence of VitD3 and/or Dex, IL-10 (10 ng/ml), or in neutral (10 ng/ml of IL-2) or Th2 conditions (10 ng/ml of IL-4 and 10
 g/ml of anti–IL-12 mAb). After three rounds of stimulation, cells were characterized for cytokine production by immunoassay (A) and by intracellular
flow cytometric analysis (B). Identical results were obtained when T cells were isolated from DO11.10 RAG / . Representative results of more than five
experiments are shown.607 Barrat et al.
Figure 2. VitD3/Dex induces the development of T cells producing IL-10
only and no inflammatory cytokines upon neutralization of Th1 and Th2 polar-
izing cytokines. (A) Purified OVA-specific naive CD4  T cells were activated
under the same conditions as in Fig. 1; except that neutralizing anti–IL-12, anti–
IFN- , and anti–IL-4 mAbs were also added. After three rounds of stimulation,
cells were characterized for cytokine production by intracellular flow cytometric
analysis. Identical results were obtained when T cells were isolated from
DO11.10 RAG / . Representative results of more than five experiments are
shown. (B) Purified naive CD4  T cells from DO11.10 RAG /  mice were ac-
tivated using anti-CD3 and anti-CD28 stimulation under neutral or VitD3/Dex
conditions. After three rounds of stimulation, cells were characterized for cyto-
kine production by intracellular flow cytometric analysis. Identical results were
obtained using DO11.10 or BALB/c mice. Representative results of three exper-
iments are shown.
Figure 3. VitD3/Dex induces the development of human T cells producing IL-10 and no IL-4, IL-5, or IFN- . Purified human CD4 CD45RA 
were stimulated with plate-bound anti-CD3, soluble anti-CD28, and IL-2 in the presence of neutralizing anti–IL-4, anti–IFN- , and anti–IL-12
mAbs. After four rounds of stimulation, cells were characterized for cytokine production by immunoassay (A) as well as by intracellular flow cyto-
metric analysis (B). Representative results of four experiments are shown.608 In Vitro Generation of Regulatory CD4  T Cells
using the combination Vit/Dex, all in the presence of neu-
tralizing mAbs to IL-12, IFN- , and IL-4. 1 d before the
cell transfer, OVA adsorbed to Alum was injected intracra-
nially to provide a reservoir of antigen for activating the
regulatory T cell population. Only cells induced with the
combination of Vit/Dex were able to prevent EAE with
absolute abrogation of disease onset and absence of clinical
signs, which is consistent to what was observed in vitro re-
garding cytokine production (Fig. 4 A). The EAE inci-
dence was 30–70% in the BALB/c mice where disease was
induced in the presence of, no cells, or T cells driven un-
der neutral, Th1, Vit alone, or Dex alone, while in the
mice treated with the Vit/Dex T cell group the incidence
of EAE was  15% (with only 7% of the mice reaching
over grade 1 of the disease; Table I). Th2 cells conferred
incomplete and marginally significant protection (Fig. 4 A
and Table I). Identical results were obtained when IL-10–
producing regulatory T cells were generated with Vit/Dex
obtained from DO11.10 RAG /  mice, and furthermore
when derived in the absence of APCs (data not shown). In
a more severe model of EAE using a genetically susceptible
strain derived from BALB/c   SJL/J (CSJLF1/J mice
[45]), the IL-10–producing T regulatory cells induced by
Vit/Dex completely prevented death and delayed the on-
set of the disease (Fig. 4 B). Furthermore, although in the
CSJLF1/J mice, the incidence of EAE in the mice injected
with Vit/Dex-derived IL-10–producing cells was 64%
compared with  90% in the no cells group, importantly,
only 21% of the mice reached over grade 3 with all the
mice recovering from the disease, compared with control
groups where  90% of the mice reached over grade 3
with accompanying mortality (Table I). In contrast, Th2
cells that gave minor protection using the BALB/c model
did not confer any protection in the CSJLF1/J mice model
(data not shown). In untreated CSJLF1/J mice, intense
mononuclear infiltrates in the white matter of the spinal
cord correlated with the clinical symptoms of EAE. In
contrast, recipients of IL-10–producing T regulatory cells
derived in the combination of Vit/Dex were EAE resistant
and spinal cords showed reduced inflammatory infiltrates
that were restricted to the perivascular spaces of the white
matter (Fig. 4 C).
IL-10 Is a Positive Autocrine Factor that Acts Directly on the
T Cell in the Absence of APCs to Enhance the Development of
IL-10–producing T Cells. To understand the mechanisms
underlying the Vit/Dex-induced development of these IL-
10–producing T cells, we assessed the role of IL-10 and
Figure 4. IL-10–producing T cells derived in VitD3/Dex
prevent the induction of EAE: cells (1–3   106 cells per
mouse) activated in the presence of neutralizing anti–IL-12,
anti–IFN- , and anti–IL-4 mAbs as described in Fig. 2 with
a combination of VitD3/Dex, in the presence of VitD3 or
Dex alone, or as controls under neutral, Th1, or Th2 condi-
tions were injected into BALB/c (A) or CSJLF1/J mice (B
and C) as indicated on the plots, 24 h after intracranial injec-
tion of OVA/Alum. EAE was then induced as described
(thin line, no cells: thick line, cells developed in vitro as de-
scribed). The experiments each were performed using 5–10 mice per group and all mice included in the groups were used in the analysis. One represen-
tative experiment of five is shown (so 40–50 mice per group in total were analyzed in the BALB/c, 25–35 in the CSJLF1/J mice) although the total
number of experiments is presented in Table I. (C) Sections of spinal cord were stained with hematoxylin and eosin for light microscopy as described
(reference 45). Arrows indicate the white matter of the spinal cord. Original magnification was 100 .
Table I. Incidence of EAE in both BALB/c and CSJLF1/J Mice
BALB/c mice CSJLF1/J mice
Disease
incidence
No. of mice
over grade 1
Disease
incidence
No. of mice
over grade 3
No cells 31/50 (62%) 28/50 (56%) 30/32 (94%) 29/32 (91%)
Neut 24/40 (60%) 22/40 (55%) 28/30 (93%) 28/30 (93%)
VitD3 24/45 (53%) 22/45 (49%)
Dex 27/45 (60%) 25/45 (56%)
Vit/Dex 6/45a (13%) 3/45a (7%) 18/28b (64%) 6/28a (21%)
Th1 27/40 (68%) 26/40 (65%)
Th2 22/40 (55%) 15/40c (38%)
Statistical analyses were performed using the  2 method.
aDifference with no cells group is statistically significant (P   0.0001).
bDifference with no cells group is statistically significant (P   0.01).
cDifference with no cells group is statistically marginally significant (P   
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TGF-  in this process. Using the antigen and APC stimu-
lation cultures of DO11.10 T cells as described earlier in
Fig. 2 A, we demonstrated that the differentiation of IL-
10–producing T cells was significantly abrogated when a
neutralizing anti–IL-10R mAb, but not an anti–TGF- 
mAb, was simultaneously added to the culture (Fig. 5 A).
No extra additive effect was observed when both neutraliz-
ing anti–IL-10R and anti–TGF-  mAbs were present in
the culture (data not shown). Furthermore, the addition of
anti–IL-10R did not have any effect on the cells driven in
neutral conditions in the presence of the neutralizing anti–
IL-4, IL-12, and IFN-  mAbs (data not shown). As IL-10
has a strong effect on APCs, we wished to determine
whether its effect was solely APC mediated. Similar exper-
iments using the APC-free system, where T cells were
stimulated with anti-CD3 plus anti-CD28, showed that
neutralization of IL-10 significantly inhibited the develop-
ment of the IL-10–producing cells in response to Vit/Dex
from 74 to 50% (anti-CD3/anti-CD28 only; Fig. 5 B) and
from 76 to 26% (anti-CD3/anti-CD28 plus neutralizing
anti–IFN-  and anti–IL-4 mAbs) of single IL-10–produc-
ing T cells (Fig. 5 C). Furthermore, the addition of anti–
IL-10R in the culture increased the number of IL-4–pro-
ducing cells (from 10 to 22%, Fig. 5 B; and from 0 to 8%,
Fig. 5 C) and of IL-2 producing cells (from 4 to 54%, Fig.
5 B; and from 15 to 78%, Fig. 5 C). These results demon-
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strate for the first time that IL-10 is a positive autocrine fac-
tor that acts directly on the T cell in the absence of APCs
to enhance the development of IL-10–producing T cells,
which is in contrast to its negative feedback role in the de-
velopment of both Th1 and Th2 responses (20). However,
as IL-10–producing T cells only developed when stimu-
lated in the presence of Vit/Dex, this shows clearly that IL-
10 is required but not sufficient for this process.
Prevention of EAE by IL-10–producing T Cells Is Abrogated
by Administration of Anti–IL-10R mAbs In Vivo and Requires
Antigenic Stimulation in the Central Nervous System. The reg-
ulatory function of these IL-10–producing cells was com-
pletely abrogated when a neutralizing anti-IL10R mAb (1
mg per mouse) was simultaneously administered in vivo at
the time of T cell transfer (Fig. 6 A), demonstrating that
IL-10 plays a crucial role for the function as well as the de-
velopment of these regulatory T cells. Moreover, the pre-
vention from EAE by the Vit/Dex induced IL-10–pro-
ducing T cells did not occur in mice that received alum
intracranially in the absence of OVA, demonstrating that
these cells require antigenic stimulation in order to func-
tion (Fig. 6 B). Furthermore, if OVA (10  g per mouse)
was delivered intraperitoneally this was not sufficient to
induce the action of the IL-10–producing regulatory T
cells. This dose of OVA was chosen since it is sufficient to
prime T cells in the periphery but on the other hand
would be at too low a dose to penetrate the central ner-
vous system (CNS). Under these conditions the IL-10–
producing cells failed to inhibit EAE, in contrast to when
OVA was delivered intracranially where full protection
was observed (Fig. 6 B). However, experiments were also
performed with a higher dose of OVA (1 mg per mouse)
Figure 5. IL-10 is a positive autocrine factor to
enhance the development of IL-10–producing T
cells induced by Vit/Dex. (A) Cells were activated
as in Fig. 2 in the combination of Vit/Dex, plus neu-
tralizing anti–IL-12, anti–IFN- , and anti–IL-4 mAbs
in the absence or presence of either anti–IL-10R (10
 g/ml) or anti–TGF-  (10  g/ml). Additionally, T
cells were stimulated using anti-CD3 and anti-CD28
with Vit/Dex in the absence (B) or presence of neu-
tralizing anti–IFN-  and anti–IL-4 mAbs (C), in the
presence or absence of anti–IL-10R mAbs. After
three rounds of stimulation, cells were characterized
for cytokine production by intracellular flow cyto-
metric analysis. Representative results of five exper-
iments are shown.611 Barrat et al.
delivered intraperitoneally and under these conditions, the
IL-10–producing regulatory T cells were still unable to
prevent the disease (data not shown). Taken altogether,
this suggests that these cells have to be activated to pro-
duce IL-10 at the site of inflammation in order to manifest
their regulatory function.
Transcription Factors Involved in Th1 and Th2 Differentiation
Are Downregulated in IL-10–producing T Cells. Key tran-
scription factors have been associated with the differenti-
ation of Th1 and Th2 cell subsets (47, 48). Indeed, it has
been shown that erm was expressed only in Th1 cells and
is induced by IL-12 in a Stat4-dependent manner, but its
function is as yet unknown (49). Also, T-bet was shown to
be restricted to Th1 cells and it has been shown that ec-
topic expression of T-bet both transactivates the IFN- 
gene and induces endogenous IFN-  production (43).
Moreover, introducing T-bet into polarized Th2 cells
could redirect them toward a Th1 phenotype producing
IFN-  and low amounts of IL-4 (43). Similarly, c-maf and
GATA-3 are selectively expressed in Th2 cells. C-maf can
direct the expression IL-4 and plays an important role in
Th2 differentiation (50), while GATA-3 has been shown
to induce Th2 cytokines when introduced into develop-
ing Th1 conditions demonstrating its predominant role
in Th2 differentiation (41, 51–53). We thus assessed the
transcription level of T-bet, erm, GATA-3, and c-maf in
the population of cells driven either using OVA and APCs
(as in Fig. 2 A) or using anti-CD3 and anti-CD28 (as in
Fig. 5 B), both in the presence of neutralizing anti–IFN- ,
anti–IL-12, and anti–IL-4 mAbs. In accordance with the
previous published findings (41–43, 50–53), the controls
in our system showed identical profiles of reciprocal ex-
pression of erm and T-bet versus c-maf and GATA-3 in
Th1 and Th2 cells, respectively (Fig. 7 A). In contrast,
these transcription factors were all downregulated in the
IL-10–producing Vit/Dex-induced T cells showing that
the exclusive production of IL-10 in this population is not
resulting from a specific upregulation of one of these tran-
scription factors (Fig. 7 A).
As the combination of Vit/Dex led to enhanced IL-10
gene expression and inhibition of the Th1 and Th2 specific
transcription factors (Fig. 7 A), we then determined the effect
of the drug combination on NF- B and AP-1 activity, as
both VitD3 and Dex has been individually shown to affect
these transcription factors. We demonstrated that NF- B and
AP-1 activities are both inhibited in Vit/Dex induced regula-
tory cells as shown by EMSA when compared with cells
driven under neutral conditions (Fig. 7 B). Further studies
will of course be necessary to assess which transcription fac-
tors are crucial for the generation of regulatory cells. How-
ever, our study provides for the first time the concept that
IL-10–producing regulatory T cells must arise in vivo under
conditions where the engagement of the signaling pathways
required for Th1 and Th2 development is minimal.
Discussion
IL-10–producing T cells distinct from Th1 and Th2 cells
have been described that undoubtedly play a role in regu-
lating inflammatory pathologies, but factors determining
their development are unknown. We report in this study
the isolation of such a population of CD4  T cells, that
produce IL-10 and no IL-4, IL-5, or IFN- , which was
able to prevent autoimmune disease when adoptively trans-
ferred in two mouse models of central nervous inflamma-
tion. This population was only induced when the im-
munosuppressive drugs VitD3 and Dex were used in
combination, together with stimulation of the cells through
their TCR, while using these drugs individually did not
lead to the generation of such regulatory cells. We also
showed that these IL-10–producing cells can develop inde-
pendently of Th1 and Th2 polarizing cytokines which
conversely were shown to inhibit the development of these
regulatory T cells in vitro. Although not sufficient for the
Figure 6. Prevention of EAE by IL-10–producing T cells derived in VitD3/Dex is abrogated by administration of anti-IL-10R mAbs in vivo and re-
quires antigenic stimulation in the CNS. (A) Cells activated in the presence of neutralizing anti–IL-12, anti–IFN- , and anti–IL-4 mAbs as described in
Fig. 2 with a combination of VitD3/Dex were injected into BALB/c mice 24 h after intracranial injection of OVA (thin line, no cells: thick line, cells).
Anti–IL-10R mAbs or isotype control (1 mg per mouse) was delivered to the mice 1 h before administration of regulatory T cells as well as once a week
during the course of the experiment. (B) Alternatively, cells activated with a combination of VitD3/Dex also were injected into CSJLF1/J mice, after in-
tracranial injection of Alum alone (No OVA, left panel); after injection of OVA, intraperitoneally (i.p.; 10  g in Alum, middle panel) or after intracranial
(i.c.) injection of OVA (right panel). As control, OVA was also injected intraperitoneally at a higher dose (1 mg in Alum) but the experiments gave sim-
ilar results. The experiments each were performed using 5–10 mice per group and all mice included in the groups were used in the analysis. One repre-
sentative experiment of three is shown.612 In Vitro Generation of Regulatory CD4  T Cells
development of regulatory T cells, endogenous IL-10 de-
livered a positive signal to these IL-10–producing T cells
during their generation with Vit/Dex. Furthermore, our
data suggests that the development of such regulatory T
cells occurs under conditions where the expression and/or
activation of key transcription factors involved in Th1 and
Th2 differentiation as well as NF- B and AP-1 is minimal.
A likely in vivo counterpart of these regulatory T cells
are the allospecific IL-10–producing T cells which have
been suggested to account for tolerance in patients with
SCID transplanted with HLA-mismatched hematopoietic
stem cells (17). Other studies have shown that chronic anti-
genic stimulation in vivo can lead to the generation of IL-
10–producing T cells and suggest how these cells may play
a physiological role in regulating undesirable immune re-
sponses (54, 55). Thus, this type of IL-10–producing regu-
latory T cell population may arise from chronic encounter
of self-antigens on subsets of specialized APCs e.g., DCs,
resident in particular organs or particular stages of maturity
(18, 19), and in the absence or low activation of the innate
immune response normally required for the generation of
inflammatory responses required to eradicate pathogens
(56). In addition, on a functional basis, the mouse CD4 
CD45RBlow T cells have been shown to act via IL-10 to
inhibit inflammatory bowel disease (IBD) and this hetero-
geneous population is likely to contain such IL-10–produc-
ing cells but in addition also Th2 cells (5, 9, 57). Although
much evidence supports the existence of regulatory T cells
in vivo, the signals required for their development are still
largely unknown. It was recently reported by Jonuleit et al.
that immature DCs can stimulate T cells toward a pheno-
type of IL-10 producers with low proliferative capacity
(18). Interestingly, both VitD3 and Dex have been shown
to affect DC maturation (28, 46) which may account for
the generation of regulatory T cells in our study. It is possible
that endogenous levels of both VitD3 and glucocorti-
coids play a role in dampening immune responses to self-
antigens during development thus avoiding the development
of pathology inducing autoreactive T cells. Macro-
phages have been shown to synthesize VitD3 upon activa-
tion with LPS and IFN-  (58), suggesting that upon
triggering of APCs by microbial factors VitD3 is synthe-
sized by these cells and thus may regulate the production of
inflammatory mediators. Furthermore, glucocorticoids re-
leased from the adrenal glands in response to stress can have
profound effects on the immune system (59). In addition, it
has been demonstrated that genetic variation in the magni-
tude of such stress responses and the release of glucocorti-
coids can determine susceptibility to an experimental au-
toimmune disease (59, 60). Other immunosuppressive
Figure 7. Transcription factors involved in Th1 and Th2 differentia-
tion are downregulated in IL-10–producing T cells. (A) Expression level
of T-bet, erm, GATA-3, and c-maf was assessed by Taqman in T cells
developed under neutral (Neut), VitD3 alone, Dex alone, and Vit/Dex in
the presence of neutralizing antibodies for IL-4, IL-12, and IFN-  using
APC/OVA stimulation as described in Fig. 2 A or anti-CD3/anti-CD28
as described in Fig. 5 C. (B) NF- B and AP-1 activities were evaluated
using 1–2  g of nuclear extracts from cells developed under neutral con-
ditions or Vit/Dex as described in Fig. 2 A. One representative experi-
ment of three is shown.613 Barrat et al.
drugs may also favor regulatory cells development in this in
vitro–driven situation (61).
The Tr1 cells that were derived in vitro in the presence
of exogenous IL-10 or in the presence of IL-4 with IL-10
(21) present similarities but also have numerous differences
with the single IL-10–producing cells derived in our study
with VitD3 and Dex. First of all, Tr1 cells not only pro-
duce IL-10 but in addition a large amount of inflammatory
cytokines such as IL-5 and IFN-  (21). To support this,
Levings et al. recently defined human Tr1 cells as IL-10
and IFN-  positive cells, and their use of IFN-  as a possi-
ble cofactor to enhance the development of these cells,
suggested that IL-10 is not sufficient to generate human IL-
10–producing T cells (23). This is not the case with cells
derived with VitD3/Dex described herein, which produce
only IL-10 and no IFN- , IL-4, or IL-5 when cultured in
the presence of anti–IL-4, anti–IL-12, and anti–IFN- 
(Fig. 2 A). Second, as shown in Fig. 1 and as already sug-
gested in other studies (22), addition of exogenous IL-10
during antigenic stimulation led to heterogeneous popula-
tions of T cells producing IL-4 and thus resembling Th2
cells. Furthermore, culture of T cells in the presence of IL-
10 but in the absence of IL-4 generates cells which produce
no IL-10 (Fig. 2 A, and data not shown using IL-4 KO
mice). This is totally in contrast with the IL-10–producing
T cells driven in our study with Vit/Dex which produce
IL-10 and no IL-4, IL-5, or IFN- , and furthermore
whose development does not require, but can be inhibited
by IL-4 (Fig. 2). Most importantly, the cells derived in our
study with Vit/Dex in the absence of Th1 and Th2 polar-
izing cytokines proliferate, in contrast to the Tr1 cells
which do not. The fact that Th1 and Th2 polarizing cyto-
kines downregulated the number and purity of IL-10–pro-
ducing regulatory T cells resulting from culture in Vit/Dex
provides a novel concept regarding the control of regula-
tory T cells by Th1 and Th2 cells, and has significant impli-
cations for the physiological interplay between these cells
during an immune response.
We have obtained IL-10–producing cells using a combi-
nation of two drugs, Vitamin D3 and Dexamethasone (Vit/
Dex). Interestingly, despite their well documented role in
inducing cytokine genes in both Th1 and Th2 subsets,
none of the T-bet, erm, GATA-3, or c-maf genes appeared
responsible for the specific activation of the IL-10 gene in
the Vit/Dex-induced cells, as their expression was inhib-
ited in T cells induced with Vit/Dex while IL-10 mRNA
expression is dramatically induced in these cells. These re-
sults question whether one or few specific transcription fac-
tors are specific for the induction in vivo of such a popula-
tion of regulatory cells. The use of the IL-10–producing
cells derived in our study will of course be of advantage in
order to answer this question. We also show herein that
signaling pathways known to be affected by both these
drugs including AP-1 and NF- B activities are inhibited in
these cells as compared with cells driven under neutral con-
ditions. Taken together, this suggests that IL-10–producing
regulatory T cells arise in vivo under conditions where the
engagement of the signaling pathways previously described
to be important for the regulation of cytokine genes pro-
duced by Th1 and Th2 cells is minimal. These observations
that transcription factors and signaling pathways shown to
be involved in the activation of Th1 and Th2-type cyto-
kine genes and thus leading to inflammation, are reduced
in the IL-10–producing regulatory T cells developed in our
study support the concept that the effect of the immuno-
suppressive drugs on the development of regulatory T cells
producing IL-10 is likely to mimic events that occur during
development as autoreactive T cells encounter antigen in
the periphery under tolerogenic conditions. Furthermore,
our data suggest that in contrast to other cytokine genes,
IL-10 gene regulation is not only refractory to the inhibi-
tory action of VitD3 and Dex, but conversely is induced by
the synergistic action of the signaling pathways induced by
these drugs (Fig. 2). A reciprocal synergistic action of these
drugs was also apparent with respect to the downregulation
of IL-2 (Fig. 2 A, middle panel).
The use of regulatory T cells in adoptive immunother-
apy has been hindered first by the contamination of such
populations with Th1- or Th2-derived cytokines that may
exacerbate inflammatory pathologies, and second by the in-
ability to expand them in large numbers. The IL-10–pro-
ducing regulatory T cells derived by the strategy presented
here do not suffer these limitations. They could indeed be
produced as a homogeneous population after stimulation of
T cells with the antigen of interest, and for example adop-
tively transferred into patients suffering from GVHD, or-
gan-specific autoimmune disorders, or other inflammatory
diseases. Alternatively, such populations could be generated
to respond either to a well-defined self-antigen or to an
unrelated protein antigen provided that the T cells are ap-
propriately triggered and thus could function as regulators
via a bystander mechanism. Other studies describing T cells
mediating bystander suppression of pathology-inducing T
cells (EAE, diabetes, IBD) support the notion that regula-
tory T cells when located at the site of inflammation could
effectively downregulate an immune response (21, 62, 63).
Generating regulatory T cells specific for a distinct antigen
to that which the pathogenic T cells react to could be a
strategy to inhibit inflammation and autoimmune manifes-
tations where the antigen is unknown. However, this still
needs to be addressed in clinical situations. Initially IL-10–
producing T cells generated with VitD3/Dex are more
likely to be used in situations where the antigen is well de-
fined such as GVHD or organ transplantation.
There is a clear paradox of how regulatory T cells prefer-
entially inhibit T cell responses to distinct antigens, while
simultaneously allowing responses to pathogens to occur.
Clearly there are various thresholds imposed to regulate the
activation of T cells, including positive and negative signals
delivered to T cells from the APCs that may differ accord-
ing to the previous activations encountered by the T cell
(64, 65). In addition, signals from the innate immune re-
sponse required to overcome negative signals delivered to
the T cell or the APC (66), or the distribution of antigen
and the recirculation patterns of T cells, may determine
whether a T cell is activated or suppressed (65, 67, 68). Fi-614 In Vitro Generation of Regulatory CD4  T Cells
nally, the ratio of regulatory T cells to effector T cells will
undoubtedly also contribute to the outcome of whether an
immune response or tolerance ensues (65).
The relationship between IL-10–producing regulatory T
cells and other described populations of regulatory T cells
(9, 11, 17, 69–73) is still unknown. Our ability to generate
homogeneous populations of regulatory cells in vitro with
Vit/Dex will certainly be key in order to address this issue.
Indeed, we have generated IL-10–producing T cells using
CD4  T cells from DO11.10 RAG /  mice, which are
known not to contain CD4 CD25  cells (74). CD45RBlow
CD4  T cells can inhibit CD45RBhighCD4  T cell–medi-
ated colitis via the action of both TGF-  and IL-10 (9, 57),
suggesting a role for both cytokines in regulation of mu-
cosal inflammation. A role for TGF-  has also been dem-
onstrated for a number of T regulatory populations, in-
cluding Th3 and Tr1 cells, in inhibition of autoimmune
pathologies, gut inflammation, and/or proliferation of anti-
gen-specific T cells (8, 21). In addition to its broad antiin-
flammatory properties, TGF-  has been shown to inhibit
the development of both Th1 and Th2 responses (75–77).
As we now show that Th1 and Th2 cytokines can down-
regulate the development of IL-10–producing regulatory T
cells, this may explain some of the effects of TGF-  to in-
hibit inflammatory pathologies, as well as its relationship
with regulatory T cells (8).
Our studies now demonstrate that IL-10–producing reg-
ulatory T cells require antigenic stimulation to function to
regulate EAE. As protection was only observed when the
antigen was delivered intracranially but not intraperito-
neally, this strongly suggests that the regulatory cells require
activation at the site of inflammation. Furthermore, the in-
hibition of EAE by these OVA-specific T cells was via a
bystander fashion, as they are inhibiting autoreactive T cells
responding to CNS-specific antigens and require IL-10 for
their function.
In conclusion, our present findings describing the gener-
ation of homogeneous populations of IL-10–producing
regulatory T cells has allowed us to determine some of the
regulatory mechanisms underlying their development and
function. Our study will facilitate their potential use in
clinical intervention and will be key to further understand
the molecular events required for the differentiation and
function of these cells.
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